Market Overview

BiotechAlert: Dendreon (NasdaqGS: DNDN) Trades Up on Revenue News


Point Roberts, WA - January 5, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Dendreon Corporation (NasdaqGS: DNDN). The stock is trading up at $10.57, up 2.97 (39.08%) 3:20PM with a day's high of$11.74.

The Company today reported revenue for the fourth quarter ended December 31, 2011, reporting gross product revenue of approximately $82 million. This represents approximately 25% growth over the third quarter ended September 30, 2011, and approximately 230% growth compared to the fourth quarter ended December 31, 2010. In addition, Dendreon reported full-year gross revenues from PROVENGE� (sipuleucel-T) sales of approximately $228 million. Newswire

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.

Get biotech news and stock alerts

Research more biotech stocks at the Biotech stocks Directory:

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow on Twitter!/Investorideas

Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

800-665-0411 - Source -

Posted-In: Global General


Related Articles (ACI)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial
Book A Demo
Learn How You Can Succeed In The Market With Benzinga Pro

Fastest Market News

Real-Time News Alerts

Customizable News Filters

Book A Demo

Saba Appoints Elaine Kitagawa Chief Financial Officer

Transocean Ltd. Announces Senior Management Changes; CFO to Step Down